sq-23377 and Carcinoma--Non-Small-Cell-Lung

sq-23377 has been researched along with Carcinoma--Non-Small-Cell-Lung* in 2 studies

Other Studies

2 other study(ies) available for sq-23377 and Carcinoma--Non-Small-Cell-Lung

ArticleYear
Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism.
    Cancer research, 2003, Feb-01, Volume: 63, Issue:3

    T lymphocyte survival is critical for the development and maintenance of an effective host antitumor immune response; however, the tumor environment can negatively impact T-cell survival. Lymphocytes exposed to tumor supernatants (TSNs) were evaluated for apoptosis after mitogen stimulation. TSN was observed to significantly enhance phorbol 12-myristate 13-acetate/ionomycin- and anti-CD3-stimulated lymphocyte apoptosis. Enhanced lymphocyte apoptosis was associated with an impairment of nuclear factor kappa B nuclear translocation and diminished I kappa B alpha degradation. In lymphocytes stimulated after exposure to TSNs, cytoplasmic I kappa B alpha persisted as a result of alterations in I kappa B kinase (IKK) activity. Accordingly, although there were no apparent differences in IKK component concentrations, lymphocytes preexposed to TSNs exhibited markedly reduced IKK activity. We conclude that non-small cell lung cancer-derived soluble factors promote apoptosis in activated lymphocytes by an IKK-dependent pathway.

    Topics: Adenocarcinoma; Apoptosis; Carcinoma, Non-Small-Cell Lung; CD3 Complex; Humans; I-kappa B Kinase; I-kappa B Proteins; Ionomycin; Jurkat Cells; Lung Neoplasms; NF-kappa B; Protein Serine-Threonine Kinases; T-Lymphocytes; Tetradecanoylphorbol Acetate

2003
Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma.
    Cancer immunology, immunotherapy : CII, 2000, Volume: 48, Issue:11

    The purpose of this work was to assess the capacity of tumor-infiltrating leukocytes (TIL) from human non-small-cell lung carcinoma (NSCLC) specimens to synthesize type-1 and type-2 cytokines.. TIL were isolated from tumors following digestion with collagenase/DNase and further enriched by ficoll-hypaque gradient centrifugation. Membrane phenotypes and intracellular cytokine protein expression of TIL were assessed by flow cytometry.. The majority of TIL expressed the CD3 antigen with a CD4:CD8 ratio of approximately 2:1. Other leukocytes such as macrophages (CD14), B lymphocytes (CD20), and natural killer (NK) cells (CD56) were also found to infiltrate the tumors, but in significantly lower numbers. Owing to the limited recovery of non-CD3(+) leukocytes, our analysis of cytokine biosynthesis has focused on T lymphocytes. In the absence of activation, a small percentage of CD3(+) TIL synthesized cytokines ( <4%). Following activation with anti-CD3+interleukin-2 (IL-2), CD3(+) TIL synthesized predominantly a type-1 cytokine profile; however, the type-2 cytokines, IL-6 and IL-10, were also detected in a small percentage of infiltrating cells. Following activation with phorbol 12-myristate 13-acetate + ionomycin, CD3(+) TIL also expressed more type-1 than type-2 cytokines and in significantly greater numbers of cells. The CD3(+)CD8(+) component of the TIL synthesized only type-1 cytokines, whereas the CD3(+)CD4(+) component synthesized both type-1 and type-2 cytokines.. These results show that the majority of the TIL isolated from NSCLC specimens are T lymphocytes with the capacity to synthesize type-1 cytokines.

    Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD3 Complex; Cytokines; Gene Expression Regulation; Humans; Interleukin-2; Ionomycin; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Muromonab-CD3; T-Lymphocytes; Tetradecanoylphorbol Acetate

2000